KMT2A and leukemia: Preclinical studies using genetic or small molecule inhibitors demonstrated that DOT1L methyltransferase activity is required for MLL-fusion–mediated leukemogenesis and validated DOT1L as a promising therapeutic target for the treatment of MLL-rearranged leukemia [15,16,19,20,56,57].